EMA Accepts GSK's Filing for Linerixibat in Rare Disease-Related Itch

• click to rate

  Posted by Two Blokes Jun 24 - Filed in Stock - 2 views
  
  GSK's marketing application for linerixibat, targeting cholestatic pruritus in PBC patients, gains EMA acceptance based on phase III success.